Skip to main content

Table 1 Baseline characteristics at inclusion, median values (range)

From: Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis

 

Group UnCh (N=142)

Group InCr (N=34)

Group DeCr (N=173)

All (N=349)

P-value*

Age

58 (16–83)

56 (25–83)

57 (18–84)

58 (16–84)

0.96

Gender (% women)

62

56

68

64

0.33**

Disease duration (months)

6.0 (1–13)

3.5 (1–12)

6.0 (1–21)

6,0 (1–21)

0.10

DAS28

5.4 (0.5-7.9)

5.5 (0.5-8.0)

5.1 (2.3-8.1)

5,3 (0,5-8,1)

0.06

HAQ

0.9 (0–2.6)

1.3 (0–2.3)

0.9 (0–2.5)

0,9 (0–2,6)

0.10

ESR (mm/H)

33 (2–110)

42 (2–140)

27 (2–115)

31 (2–140)

0.006

CRP (mg/L)

22.0 (4–186)

29.5 (3–159)

19.0 (4–228)

21 (3–228)

0.40

RF positive (%)

61

67

56

59

0.46**

Anti-CCP (%)

58

61

56

57

0.86**

COMP (U/L)

11.9 (6.1-26.8)

9.6 (5.6-19.3)

13.8 (4.5-32.0)

12.7 (4.5-32.0)

<0.001

Erosion score

0 (0–44)

0 (0–20)

0 (0–15)

0 (0–44)

0.68

JSN score

0 (0–40)

0 (0–15)

0 (0–33)

0 (0–40)

0.41

Total Sharp score

1 (0–84)

2 (0–34)

0.25 (0–35)

1 (0–84)

0.52

  1. Group UnCh, patients with unchanged serum-COMP levels from inclusion to 3 months follow-up (change ≤ 20%),
  2. Group InCr, increasing serum- COMP levels from inclusion to 3 months follow-up (increase > 20%).
  3. Group DeCr, decreasing serum-COMP levels from inclusion to 3 months follow-up (decrease > 20%).
  4. *Kruskal-Wallis test, ** Chi2 test.